| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791127 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| US8747896 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Jun, 2027
(3 years from now) | |
| US8592434 | LNHC | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(6 years from now) | |
Sitavig is owned by Lnhc.
Sitavig contains Acyclovir.
Sitavig has a total of 3 drug patents out of which 0 drug patents have expired.
Sitavig was authorised for market use on 12 April, 2013.
Sitavig is available in tablet;buccal dosage forms.
Sitavig can be used as treatment of herpes labialis.
The generics of Sitavig are possible to be released after 16 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 12, 2016 |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET;BUCCAL
More Information on Dosage
SITAVIG family patents
